(Q34392465)

1 August 2017

1 reference

title

Extrapyramidal side effects are unacceptable (English)

1 reference

1 August 2017

main subject

extrapyramidal symptoms

1 reference

Kane JM

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

European Neuropsychopharmacology

1 August 2017

published in

1 reference

1 August 2017

volume

11 Suppl 4

1 reference

1 August 2017

page(s)

S397-403

1 reference

Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic Drugs

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Akathisia variants and tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

A two-year prospective study of treatment compliance in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Tardive akathisia: an analysis of clinical features and response to open therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Compliance with medication regimens for mental and physical disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Incidence of tardive dyskinesia in patients receiving depot neuroleptic injection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

A prospective study of tardive dyskinesia in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Review of quetiapine and its clinical applications in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Adverse effects of antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Prospective study of tardive dyskinesia in the elderly: rates and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Incidence of tardive dyskinesia in an outpatient population

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900109-2

7 January 2021

10.1016/S0924-977X(01)00109-2

Identifiers

DOI

1 reference

1 August 2017

1 reference